Honors and Awards
Honor

Todd M. Malynn Named “2023 Legal Visionary” by Los Angeles Times B2B Publishing

Blank Rome LLP is pleased to announce that partner Todd M. Malynn has been recognized as a “2023 Legal Visionary” in Los Angeles Times B2B Publishing's special supplement, Business of Law: Trends, Updates, Visionaries & The In-House Counsel Awards.

This year’s Legal Visionaries are recognized for their “success rate; settlements and verdicts won in the last three years (2019-2022); leadership positions within the firm and community; and board affiliations and recognitions." Each Legal Visionary was recognized with an honoree profile that shares information about their career, practice, and recent successes they’ve achieved.

To read the full "Business of Law: Trends, Updates, Visionaries & The In-House Counsel Awards" supplement, please click here


Todd's Legal Visionary profile, as published in the Los Angeles Times, is copied in full below.

malynn

Todd Matthew Malynn
Partner, Intellectual Property Litigation
Blank Rome LLP
Loyola Law School
Intellectual Property

As an experienced and well-respected trial attorney in both the Los Angeles area and nationally, Todd M. Malynn aggressively seeks to identify solutions - whether through settlement or trial - and combines his IP and business transactional experience to help identify, protect, defend, and monetize his client’s rights and interests. He represents clients in a wide range of intellectual property matters, from patent, copyright, and trademark infringement to false advertising, unfair competition, misappropriation of trade secrets, and covenants not to compete. Another element of his active litigation practice includes arguing matters under the Federal Trade Commission Act and the Medical Device Regulation Act.

Outside of the courts, Malynn manages his clients’ patent and trademark portfolios. He also represents clients before the Federal Drug Administration (FDA) in approval proceedings. His work spans numerous industries, including cosmetics, pharmaceuticals, medical devices, manufacturing, and entertainment.